Stocks › VKTX
Viking Therapeutics, Inc.
VKTX·Nasdaq·
United States·USD
United States·USD$28.38
-0.90 (-3.07%)
Close · Oct 6, 2026 · Close Prices from Tiingo.com
VKTX
Viking Therapeutics, Inc. · Nasdaq
Nasdaq 100S&P 500
Filings
Default90D1Y5YALL
VKTXS&P 500 (rebased)
Congress BuyCongress SellInsider BuyInsider SellForm 1448-K ResultsLobbying
Loading price history…
Daily closes, adjusted for splits and dividends · Close Prices from Tiingo.comHover a marker, every one is a filing · move across the line for the crosshair
Congressional Trades
Recent trades of VKTX by members of U.S. Congress · 0 on record
No congressional trades in VKTX on record.
Whale Activity
Position changes in VKTX reported for 2026-06-30 by 10 tracked institutional filers
- Increased4
- New1
- Held0
- Decreased4
- Closed0
- No prior filing1
| Filer | Shares | Value | Change |
|---|---|---|---|
| BlackRock, Inc. | 6.2M | $241.5M | decreased |
| VANGUARD CAPITAL MANAGEMENT LLC | 5.1M | $197.1M | increased |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 4.5M | $174.9M | increased |
| TWO SIGMA INVESTMENTS, LP | 3.9M | $153.6M | decreased |
| D. E. Shaw & Co., Inc. | 1.6M | $62.6M | decreased |
| CITADEL ADVISORS LLC | 951.5K | $37.1M | decreased |
| MILLENNIUM MANAGEMENT LLC | 498.2K | $19.4M | increased |
| Point72 Asset Management, L.P. | 473.3K | $18.5M | new |
| Bridgewater Associates, LP | 87.9K | $3.4M | increased |
| BRANDYWINE MANAGERS, LLC | 12.3K | $480K | — |
KeyVex tracks a curated set of large 13F filers plus the largest positions in recent filings, so this is a sample of institutional activity, not the whole market.
Insider Trading
Net shares bought (+) or sold (−) on the open market by VKTX insiders, by quarter · Form 4
Recent Insider Transactions
340 transactions on record · newest first
| Insider | Type | Shares | Price | Value | Date | |
|---|---|---|---|---|---|---|
| Lian BrianPresident & CEO · Director | Sale | −148.5K | $33.32 | $4.9M | Jul 29, 2026 | Form 4 ↗ |
| ZANTE GREGChief Financial Officer | Sale | −21.2K | $33.47 | $710K | Jul 29, 2026 | Form 4 ↗ |
| Mancini MariannaChief Operating Officer | Sale | −18.2K | $33.47 | $610K | Jul 29, 2026 | Form 4 ↗ |
| Aubuchon Neil WilliamChief Commercial Officer | Purchase | +4,475 | $33.50 | $150K | Mar 10, 2026 | Form 4 ↗ |
| ZANTE GREGChief Financial Officer | Sale | −1,500 | $32.09 | $48K | Jan 5, 2026 | Form 4 ↗ |
| ZANTE GREGChief Financial Officer | Sale | −10.3K | $34.24 | $353K | Jan 5, 2026 | Form 4 ↗ |
| ZANTE GREGChief Financial Officer | Sale | −13.9K | $33.38 | $464K | Jan 5, 2026 | Form 4 ↗ |
| ZANTE GREGChief Financial Officer | Sale | −32.0K | $32.30 | $1.0M | Jan 5, 2026 | Form 4 ↗ |
| Mancini MariannaChief Operating Officer | Sale | −1,600 | $35.07 | $56K | Jan 5, 2026 | Form 4 ↗ |
| Mancini MariannaChief Operating Officer | Sale | −10.5K | $34.22 | $359K | Jan 5, 2026 | Form 4 ↗ |
| Mancini MariannaChief Operating Officer | Sale | −13.6K | $33.37 | $454K | Jan 5, 2026 | Form 4 ↗ |
| Mancini MariannaChief Operating Officer | Sale | −32.0K | $32.29 | $1.0M | Jan 5, 2026 | Form 4 ↗ |
| Lian BrianPresident & CEO · Director | Sale | −6,400 | $35.07 | $224K | Jan 5, 2026 | Form 4 ↗ |
| Lian BrianPresident & CEO · Director | Sale | −41.3K | $34.22 | $1.4M | Jan 5, 2026 | Form 4 ↗ |
| Lian BrianPresident & CEO · Director | Sale | −53.3K | $33.38 | $1.8M | Jan 5, 2026 | Form 4 ↗ |
| Lian BrianPresident & CEO · Director | Sale | −132.5K | $32.29 | $4.3M | Jan 5, 2026 | Form 4 ↗ |
| ZANTE GREGChief Financial Officer | Grant / award | +32.0K | $0.00 | $0 | Jan 2, 2026 | Form 4 ↗ |
| ZANTE GREGChief Financial Officer | Grant / award | +41.0K | $0.00 | $0 | Jan 2, 2026 | Form 4 ↗ |
| Mancini MariannaChief Operating Officer | Grant / award | +32.0K | $0.00 | $0 | Jan 2, 2026 | Form 4 ↗ |
| Mancini MariannaChief Operating Officer | Grant / award | +41.0K | $0.00 | $0 | Jan 2, 2026 | Form 4 ↗ |
Fund Holders
Mutual funds and ETFs holding VKTX · SEC Form N-PORT
| Fund | Shares | Value | % of fund | As of |
|---|---|---|---|---|
| State Street(R) SPDR(R) S&P(R) Biotech ETF SPDR SERIES TRUST | 3.6M | $140.0M | 1.30% | Jun 30, 2026 |
| VANGUARD TOTAL STOCK MARKET INDEX FUND VANGUARD INDEX FUNDS | 3.5M | $136.5M | 0.01% | Jun 30, 2026 |
| VANGUARD SMALL-CAP INDEX FUND VANGUARD INDEX FUNDS | 2.5M | $98.6M | 0.05% | Jun 30, 2026 |
| VANGUARD SMALL-CAP GROWTH INDEX FUND VANGUARD INDEX FUNDS | 1.5M | $56.9M | 0.12% | Jun 30, 2026 |
| VANGUARD EXTENDED MARKET INDEX FUND VANGUARD INDEX FUNDS | 1.3M | $52.0M | 0.05% | Jun 30, 2026 |
| Heritage Fund American Century Mutual Funds, Inc. | 1.3M | $42.3M | 0.80% | Jul 31, 2026 |
| Fidelity Advisor Growth Opportunities Fund Fidelity Advisor Series I | 1.1M | $34.8M | 0.10% | May 31, 2026 |
| Fidelity Extended Market Index Fund Fidelity Concord Street Trust | 598.0K | $19.6M | 0.05% | May 31, 2026 |
| iShares Russell Mid-Cap ETF iShares Trust | 467.2K | $18.2M | 0.03% | Jun 30, 2026 |
| Schwab U.S. Small-Cap ETF SCHWAB STRATEGIC TRUST | 555.7K | $18.2M | 0.08% | May 31, 2026 |
Mutual funds and ETFs whose N-PORT filings list VKTX's shares (CUSIP 92686J106), each fund at its latest report since Mar 7, 2026, largest positions first. Bonds, options and short positions are left out.
Activist & Passive Stakes
Schedule 13D / 13G beneficial-ownership filings
No 13D/13G beneficial-ownership filings on record.
Corporate Lobbying
Estimated quarterly lobbying spending reported under the LDA, filings naming Viking Therapeutics, Inc. as client
No lobbying filings found naming Viking Therapeutics, Inc. as the client.
Government Contracts
Federal awards to Viking Therapeutics, Inc. · USAspending
No federal contract awards found for Viking Therapeutics, Inc..
U.S. Patents
Recent USPTO applications naming Viking Therapeutics, Inc.
No USPTO patent applications found for Viking Therapeutics, Inc..
Annual Financials
From VKTX's 10-K filings · XBRL
No annual XBRL figures on record for VKTX. KeyVex's fundamentals cover about 130 large companies so far.
Stock Splits
Every split and reverse split in the price history
No stock splits in VKTX's price history.
Material Events (8-K)
Corporate events filed with the SEC
About Viking Therapeutics, Inc.
From SEC EDGAR company records
Industry (SIC 2834)Pharmaceutical Preparations
SectorHealthcare
HeadquartersSAN DIEGO, CA
IncorporatedDE
SEC CIK0001607678 ↗